<DOC>
	<DOCNO>NCT00416923</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving rituximab intrathecally may effective treatment recurrent CNS lymphoma . PURPOSE : This phase I trial study side effect best dose intrathecal rituximab treat patient recurrent CNS lymphoma .</brief_summary>
	<brief_title>Intrathecal Rituximab Treating Patients With Recurrent CNS Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety pharmacokinetics intrathecal rituximab patient recurrent CNS lymphoma arise CD20+ B-cell non-Hodgkin 's lymphoma . Secondary - Determine efficacy intrathecal rituximab . - Determine molecular pathogenesis lymphomatous meningitis . - Determine molecular basis response lack response rituximab . - Identify molecular marker specific lymphomatous meningitis useful prognostic evaluation peripheral lymphoma . - Determine quality life patient treat intrathecal rituximab . OUTLINE : This dose-escalation , multicenter study . Patients receive rituximab intrathecally 10 minute day 1 week 1 day 1 4 week 2-5 absence disease progression unacceptable toxicity . Patients achieve least partial response rituximab-related neurotoxicity may continue receive treatment beyond 5 week . Cohorts patient receive escalate dos rituximab maximum tolerate dose ( MTD ) determine . The MTD define dose few 1/3 patient experience dose-limiting toxicity . Quality life assess baseline completion study treatment . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 10 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm relapsed CNS lymphoma Arising primary CNS lymphoma systemic nonHodgkin 's lymphoma Evidence brain parenchymal involvement , cerebrospinal fluid ( CSF ) involvement , ocular involvement radiation treatment intrathecal chemotherapy Tumors must CD20+ pathologic analysis Refractory persistent disease allow No complete obstruction CSF pathway within ventricular system unless alleviate external beam radiotherapy systemic chemotherapy No obstructive hydrocephalus PATIENT CHARACTERISTICS : Karnofsky performance status &gt; 50 % Must Ommaya reservoir Granulocyte count &gt; 1,500/mm^3 Platelet count &gt; 50,000/mm^3 Anticipated survival ≥ 1 month PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered toxicity prior therapy Prior intrathecal methotrexate , cytarabine , thiotepa CNS lymphoma allow Concurrent systemic chemotherapy treatment disease outside meninges allow except highdose methotrexate , highdose cytarabine , highdose thiotepa , investigational agent No history wholebrain craniospinal radiation &lt; 1 week study entry No history intrathecal chemotherapy &lt; 1 week study entry No concurrent intrathecal chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>leptomeningeal metastasis</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>